Dazzeon Biotech, which started off by researching plant polymer structures and material science as well as increasing the activity of plant polysaccharides, is one of the very few biotech companies in Taiwan that can merge plant polysaccharides and material science. It also puts a premium on clinical data. The company is set to demonstrate the result of commercializing its two core technologies, MannanPRO and AlphaSleep. By integrating plant polysaccharides with material science, the company has launched more natural and simpler solutions to digestive tract function and sleep problems compared with existing solutions. Moreover, the company was invited to BioJapan 2023, the largest biopharmaceutical and healthcare exhibition in Japan and Asia, making it a high-profile company in Taiwan, Japan, and the Asia-Pacific region.
Dazzeon Biotech’s AlphaSleep has a product line of αSleep Blankets, a key result of the commercialization of the company’s nano size reduction technology. The product applies AlphaSleep Power, an energy wavelength that can increase whole-body circulation. Another product line, MannanPRO, applies plant polysaccharides and has been patented in the U.S., Taiwan, and China, better utilizing the natural power of aloes.
Dr. Richard Kao, CEO of Dazzeon Biotech, also said, “According to a CDC report released in April 2021, the number of people worldwide affected by digestive tract problems is about 7 million. The global market size is estimated to be $25 billion. Dazzeon Biotech’s goal is to provide groundbreaking solutions.” Thus, the company has set up an international R&D center in the New Taipei Industrial Park. Its research partners are located in the Netherlands, Germany, Belgium, and Japan. Among them, GFP, an expert in mushroom polysaccharides from Germany, and S&K, a healthy chocolate brand from the Czech Republic, are some of the multinational companies that have started business collaboration in view of the purity of the products, literature, and the huge number of precise experimental data indicators that Dazzeon Biotech’s R&D team offers.
Dazzeon Biotech is going to Japan to participate in Asia’s largest biotechnology and pharmaceutical exhibition, which will be held at Pacifico Yokohama, Japan, from October 11-13, 2023. Three thematic exhibitions are held together, and this year marks the 25th anniversary of the event. With international exchanges such as exhibitions, seminars, and business matchmaking, the company believes that it can demonstrate Taiwan’s strong biotechnology R&D capabilities in the global biotechnology market through the commercialization of its two core technologies, MannanPRO and AlphaSleep.
Source：Economic Daily News